EG
Therapeutic Areas
Sol-Gel Technologies Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TWYNEO® (tretinoin & benzoyl peroxide) cream | Acne vulgaris | Approved |
| Epsolay® (benzoyl peroxide) cream | Papulopustular Rosacea | Approved |
| SGT-210 (erlotinib) gel | Epidermolysis Bullosa Simplex (EBS) | Phase 2 |
| SGT-310 (cannabidiol) gel | Acne Vulgaris | Preclinical |
| SGT-510 (tapinarof) cream | Acne Vulgaris | Preclinical |
Leadership Team at Sol-Gel Technologies
AS
Alon Seri-Levy
Chief Executive Officer and Director
GM
Gilad Mamlok
Chief Financial Officer
OT
Ofer Toledano
Chief Operating Officer
DC
David Cohen
Chief Medical Officer
MD
Marc D. Brown
Chief Scientific Officer
SS
Sharon Sagiv
Vice President, Regulatory Affairs
DF
Dror Futter
Vice President, Research & Development
LC
Limor Chen
Vice President, Chief Legal Officer & Corporate Secretary
DT
Dov Tamarkin
Director
ND
Nissim Darvish
Chairman of the Board